These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7928619)

  • 1. CPT-11: a novel antitumor drug.
    Armand JP
    Jpn J Cancer Res; 1994 Aug; 85(8):inside front cover. PubMed ID: 7928619
    [No Abstract]   [Full Text] [Related]  

  • 2. Schedule-dependent efficacy of camptothecins in models of human cancer.
    Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA
    Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512
    [No Abstract]   [Full Text] [Related]  

  • 3. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
    Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view].
    Taguchi T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1574-8. PubMed ID: 1651685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Irinotecan hydrochloride (CPT-11)].
    Furue H
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):709-17. PubMed ID: 8154899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
    Kim DK; Lee N
    Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
    Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
    Lavelle F; Bissery MC; André S; Roquet F; Riou JF
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].
    Furuta T; Yokokura T
    Gan To Kagaku Ryoho; 1990 Jan; 17(1):121-30. PubMed ID: 2297233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
    Lavergne O; Bigg DC
    Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPT-11 (irinotecan) in the treatment of colorectal cancer: a new mechanism of action for additional activity.
    Bleiberg H
    Tumori; 1997; 83(1 Suppl):S85-6. PubMed ID: 9154078
    [No Abstract]   [Full Text] [Related]  

  • 12. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.
    Tsuruo T; Matsuzaki T; Matsushita M; Saito H; Yokokura T
    Cancer Chemother Pharmacol; 1988; 21(1):71-4. PubMed ID: 3342468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies of CPT-11 in Japan.
    Taguchi T
    Gan To Kagaku Ryoho; 1995 Aug; 22 Suppl 3():277-83. PubMed ID: 7661595
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors.
    Kohn KW; Pommier Y
    Ann N Y Acad Sci; 2000; 922():11-26. PubMed ID: 11193886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation].
    Oguro M; Seki Y
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1556-61. PubMed ID: 1651682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future directions for clinical research with CPT-11 (irinotecan).
    von Hoff D
    Eur J Cancer; 1996; 32A Suppl 3():S9-12. PubMed ID: 8943659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
    Conover CD; Greenwald RB; Pendri A; Shum KL
    Anticancer Drug Des; 1999 Dec; 14(6):499-506. PubMed ID: 10834271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical development of camptothecins.
    Costin D; Potmesil M
    Adv Pharmacol; 1994; 29B():51-72. PubMed ID: 8996601
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity.
    Yao L; Zhao X; Li Q; Zu Y; Fu Y; Zu B; Meng X; Liu C
    Int J Pharm; 2012 Feb; 423(2):586-8. PubMed ID: 22193057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current status of irinotecan (CPT-11) in the United States.
    Rothenberg ML
    Ann N Y Acad Sci; 1996 Dec; 803():272-81. PubMed ID: 8993521
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.